Web Research
Web Research — Onyx Biotec (ONYX)
Figures converted from INR at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, growth rates and multiples are unitless and unchanged.
The Bottom Line from the Web
The filings tell you Onyx is a small WHO-GMP contract manufacturer. The internet adds the part the filings bury: the IPO thesis broke 18 months after listing. FY26 audited results (board-approved 14 May 2026) flipped a $0.58M FY25 PAT into a $0.02M net loss, foreign institutional holding collapsed from 8.72% at listing to 1.07% by Mar 2026, and the post-anchor-lockup tape shows the IPO anchors (ZETA Global Funds, Globalworth Securities) selling steadily into a stock now 48% below issue price.
Price ($)
Market Cap ($M)
vs IPO Price ($0.72)
1-Year Return
FII Holding (Mar-26)
FY26 PAT ($M)
What Matters Most
The ten findings below are the entire web-research case file ranked by how much each changes the investment view. Material events come first; texture and background later.
1. FY26 swung from profit to loss — the IPO "super-earnings" thesis broke
Audited FY26 results (board 14 May 2026): revenue $7.45M (+10.8% YoY) but a net loss of $0.02M vs PAT $0.58M in FY25 — a 104% swing on the bottom line. Operating margin collapsed from 16.39% to 4.86%. Net margin from 7.99% to -0.30%. The FY25-annualised story brokers used to justify the IPO has been invalidated.
The IPO reviewer Dilip Davda flagged this risk explicitly pre-IPO: "marked inconsistency in its top lines… highly fluctuating bottom lines raises eyebrows. Based on FY25 super earnings, the issue appears fully priced." That warning has aged perfectly. Source: scanx.trade FY26 results; Chittorgarh IPO review.
2. FII holding has collapsed from 8.72% to 1.07% — 88% exit in 16 months
Quarterly shareholding tape (Screener.in): FII 8.72% (Nov-24) → 5.36% (Mar-25) → 1.95% (Sep-25) → 1.07% (Mar-26). The named sellers are the IPO anchors themselves — ZETA Global Funds (Series B & C) and Globalworth Securities — exiting in tranches as anchor lockups rolled off.
Trendlyne bulk-deal disclosures itemise the exits: ZETA Series B sold 374,000 shares @ $0.51 on 18 Sep 2025; Globalworth sold 176,000 @ $0.58 on 11 Aug 2025 and 104,000 @ $0.56 on 16 Sep 2025; ZETA Series C sold 154,000 @ $0.34 on 30 Mar 2026 and Globalworth sold 190,000 @ $0.34 the same day. Smart money exited; the stock cratered through their exit prints. Source: Screener shareholding; Trendlyne bulk deals.
3. Stock is -47.5% below IPO price and -42.9% below 52-week high
$0.33 spot vs $0.72 IPO issue (Nov 2024) — a 47.5% drawdown from issue; $0.58 52-week high → -42.86%. Onyx listed at $0.64 (-11.4% to issue) on 22 Nov 2024 despite IPO oversubscription of 198x overall (NII 602x, retail 118x, QIB 32.5x). One-year return -36.4% (ET).
The classic SME IPO froth-then-fade tape. The number of shareholders has halved from 1,181 at listing to 586 by Mar 2026 — retail is leaving as fast as institutions. Trendlyne's DVM flags Onyx as "Expensive Valuation, Technically Bearish" with a 27.6/100 momentum score. Source: Business Standard debut coverage; Livemint listing.
4. ~88.9 lakh promoter shares released from lock-up on 29 Nov 2025 — structural overhang
MarketScreener filings document two lock-up release events in the 28–29 Nov 2025 window: 734,600 shares released on 28-Nov-2025 and a much larger 8,887,600 shares released on 29-Nov-2025. Promoter cost basis is essentially zero (NIL / $0.06 / $0.06 per Chittorgarh) — at $0.33 they remain hugely in the money even after the 48% drawdown. The 3-year SME promoter lock-in on the residual locked block expires Nov-2027.
Promoter holding has been frozen at 65.10% since IPO (Naresh Kumar 24.0%, Sanjay Jain 21.5%, Fateh Pal Singh 19.6%) and no promoter pledge has been disclosed. But the lock-up release sets up a structural seller of last resort. Source: MarketScreener corporate events; Chittorgarh promoter detail.
5. Company Secretary resigned 2 months after listing — a yellow card
Harsh Jhunjhunwala resigned as Company Secretary & Compliance Officer on 22 Jan 2025 — barely two months after the 22 Nov 2024 NSE SME listing. Replaced by Ruchi Chowdhury. A CS exit inside 60 days post-IPO is unusually fast and is the canonical post-listing governance signal forensic analysts watch for.
No public reason was disclosed in the BSE/NSE filing. By itself benign; combined with the financial-controller concentration in #6 below it stops being benign. Source: MarketScreener corporate actions feed; financesaathi DRHP contact-person trail.
6. CEO + CFO + Whole-Time Director are the same person
Per Livemint's company page, Harsh Mahajan holds Whole-Time Director, Chief Executive Officer AND Chief Financial Officer roles concurrently. For a public-listed SME this concentration of executive, operating and financial-controller authority in one individual is a textbook segregation-of-duties weakness — the controls model assumes the CFO can challenge the CEO. Promoter family (Sanjay Jain MD + Lakshya Jain WTD) also dominates the executive bench.
Combined with three independents on an 8-member board (legal minimum under SEBI for SMEs) and the recent CS turnover, the audit-committee independence picture is borderline at best. SEBI's SME exemption framework allows it; sophisticated allocators won't. Source: Livemint market-stats page; Moneycontrol management.
7. No analyst coverage, no transcripts, no MF ownership — information desert
Searches across ICICI, Motilal Oswal, Kotak, Axis returned no formal sell-side coverage. Trendlyne, Moneycontrol and ET show no earnings calls and no transcripts. Livemint MF holding: "-%"; Tijori: "Insufficient data". The only third-party "research" surfaced is MarketsMojo's 11-Sep-2025 valuation grade upgrade to "very attractive" (P/E 17.67, EV/EBITDA 8.83) — issued eight months before the FY26 loss invalidated the inputs.
The implication is decision-grade: there is no consensus, no maintained estimates, no buy-side coverage to anchor a price target. Any allocator buying ONYX is doing primary research alone. Source: Trendlyne coverage page; Livemint stat page.
8. Customer wins post-IPO were operationally real but margin-dilutive
Confirmed contract events from the NSE/MarketScreener feed: (a) Innova Captab agreement for SWFI on 9 Jan 2025; (b) Mankind Prime Labs order on 7 Feb 2025; (c) Galpha Laboratories DPI agreements on 8 Apr and 24 Apr 2025; (d) DRC Congo dry-injectables export approval on 14 Jan 2026 — the first credible overseas market opening after FY24/FY25 forex earnings of NIL.
Top-line growth of +10.8% in FY26 confirms the wins are real. But operating margin compressed by ~1,150 bps over the same period — the new business is structurally lower-margin or is loading fixed costs without commensurate price. The Unit-II cephalosporin DPI ramp narrative cannot be both delivering AND collapsing margin; one of those is wrong. Source: MarketScreener events; Zerodha events.
9. ROE / ROCE figures vary 10x across sources — a stale-data problem investors will trip on
Screener.in (TTM, captures FY26): ROE -0.38%, ROCE 1.14%. Zerodha/Tijori (pre-FY26): ROE 8.91%, ROCE 12.96%. IPO RHP (FY24): ROE 10.58%, RoNW 12.19%. MarketsMojo (Sep-25): ROCE 12.26%. Livemint TTM P/E: 36.94 vs sector P/E 25.39 — a premium on near-zero earnings.
For an investor screening on financial portals, the version they land on is luck-of-the-draw. The decision-grade number is Screener's TTM (-0.38% ROE on $0.32 book value) because it reflects the most recent reported earnings. Source: Screener ratios; Livemint ratios.
10. No forensic smoking gun — but the questions don't have answers
On the positive ledger: no auditor qualification or restatement; auditor M/s R C A and Co LLP (Firm 011602N/N500350) issued an unmodified opinion for FY26; the Statement of Deviation (14-May-2026) confirms zero deviation in IPO proceeds use (net proceeds $2.63M deployed per stated objectives); no SEBI probe, no class action, no short-seller report, no fraud allegation, no promoter-pledge.
What the searches couldn't answer are the specialist questions that would matter: receivables aging on the $5.54M "other current assets" balance, the FY25 9x other-income spike composition, related-party-transaction magnitude, the LVP-line commissioning status ($0.72M of IPO proceeds earmarked), and whether the audit committee includes the CFO. The forensic file is thin not because nothing's there, but because Onyx publishes nothing beyond statutory minimums. Source: NSE filing — Statement of Deviation; Zaubacorp prosecution check (no prosecutions).
Recent News Timeline
What the Specialists Asked
Each specialist phase submitted high-priority research questions; the Parallel searches returned varied results. Below is the per-specialist Q&A with synthesised answers and confidence ratings.
Governance and People Signals
The promoter trio (Sanjay Jain MD, Naresh Kumar WTD, Fateh Pal Singh — not on board) holds 65.10% of equity with zero pledged. Their acquisition cost is essentially zero (NIL / $0.06 / $0.06 per share per Chittorgarh disclosure), so at $0.33 spot they are vastly in the money even after the 48% IPO drawdown. No promoter has filed an SAST disclosure; promoter holding has been static since listing.
The governance amber flags are concentrated in the executive layer, not the cap table.
Bulk-deal counterparty trail (post-anchor-lockup)
The named bulk-deal sellers and buyers shed light on who was inside the post-IPO bid stack and who is leaving. This is the key insider-tape evidence for the FII collapse from 8.72% to 1.07%.
The Sep-25 prints (≥ $0.51) and the Mar-26 prints ($0.34) show the FII exit absorbed a 30% price decline; the anchors did not stop selling as the price fell. Combined with the 8.9M-share lock-up release on 29-Nov-2025, the supply equation through the next 18 months is structurally negative.
Shareholding migration since IPO
Promoters frozen; FIIs gone; DIIs barely moved. The vacated FII share went to public retail — which has also nearly halved by shareholder count (1,181 → 586).
Industry Context
The industry tab carries the full primer. The web layer adds three structural points the filings do not emphasise:
1. Revised Schedule M — the regulatory tailwind narrative. CDSCO's revised Schedule M (initial deadline extended to 31 Dec 2025 for MSME pharma units) forces sub-scale, non-compliant sterile manufacturers to either upgrade or exit. Solan and Baddi are the densest MSME-pharma clusters in India. Onyx is WHO-GMP and operates two compliant units, so the theoretical tailwind is real. What's missing is the magnitude — neither the searched CDSCO Form A filing lists nor industry reports quantified how many Solan/Baddi units have already exited or will. Without that number the tailwind is narrative, not earnings.
2. The peer set Onyx wants to compare itself to is not its real peer set. The RHP cherry-picked Suven Pharmaceuticals (~$10.9B m-cap, P/E 83.92, RoNW 14.64%) and JB Chemicals (~$36.1B m-cap, P/E 53.63, RoNW 18.90%) — both 1,800-6,000× larger than Onyx's $6.0M m-cap. The real peer set is Aculife Healthcare (Nirma sub), Otsuka Pharmaceutical India, Albert David, Denis Chem Lab, Parenteral Drugs (India), Akums Drugs & Pharmaceuticals, Innova Captab, Senores Pharmaceuticals. None of these surfaced as named competitor analytics in the seven search files — a research gap. Tracxn lists 878 active competitors in the broader segment with Onyx ranked #387.
3. Cephalosporin DPI is a low-growth global drug class (~3% CAGR). Onyx's Unit II ramp narrative depends on share-taking, not market growth. The cephalosporin global volume base is mature; growth has to come from contract wins against Akums, Innova Captab (Kathua block), Aurobindo, Lupin, Hetero, Aristo — most multiple orders of magnitude larger. The FY26 Galpha and Mankind Prime Labs contracts are credible incremental wins; they are not a category-share story.